2′-deoxy-2′-spirocyclopropylcytidine revisited: A new and selective inhibitor of the hepatitis C virus NS5B polymerase

Journal of Medicinal Chemistry

Volumn 53, Issue 22, 2010, Pages 8150-8160

  Jonckers, Tim H M ^a   Lin, Tse I ^a   Buyck, Christophe ^a   Lachau Durand, Sophie ^a   Vandyck, Koen ^a   Van Hoof, Steven ^a   Vandekerckhove, Leen A M ^a   Hu, Lili ^a   Berke, Jan Martin ^a   Vijgen, Leen ^a   Dillen, Lieve L A ^a   Cummings, Maxwell D ^a   De Kock, Herman ^a   Nilsson, Magnus ^b   Sund, Christian ^b   Rydegård, Christina ^b   Samuelsson, Bertil ^b   Rosenquist, Åsa ^b   Fanning, Gregory ^a   Van Emelen, Kristof ^a   Simmen, Kenneth ^a   Raboisson, Pierre ^a   more..

^a TIBOTEC BVBA   (Belgium)

^b MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; 2' DEOXY 2' SPIROCYCLOPROPYLCYTIDINE; 2' METHYLCYTIDINE; 4 AMINO 1 [7 HYDROXY 6 HYDROXYMETHYL 5 OXASPIRO (2 4) HEPT 4 YL] PYRIMIDIN 2 ONE DERIVATIVE; 4' AZIDOCYTIDINE; [4 (4 AMINO 2 OXOPYRIMIDIN 1(2H) YL) 6 (ISOBUTYRYLOXYMETHYL) 5 OXASPIRO (2 4) HEPT 7 YL) ISOBUTYRATE; [4 (4 AMINO 2 OXOPYRIMIDIN YL) 6 HYDROXYMETHYL 5 OXASPIRO (2 4) HEPT 7 YL] ISOBUTYRATE; CYTIDINE DERIVATIVE; NONSTRUCTURAL PROTEIN 5B; NUCLEOSIDE; RNA DIRECTED RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; 2'-DEOXY-2'-SPIROCYCLOPROPYLCYTIDINE; ANTIVIRUS AGENT; CYTIDINE; DRUG DERIVATIVE; ESTER; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; PRODRUG; RNA DIRECTED RNA POLYMERASE; SPIRO COMPOUND; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL DOG; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DOG; DRUG ANTAGONISM; DRUG EFFECT; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CYTIDINE; DOGS; ESTERS; HEPACIVIRUS; HUMANS; MALE; MODELS, MOLECULAR; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; RNA REPLICASE; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 78649510531     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101050a     Document Type: Article

References (60)

1. Ghobrial, R. M.; Steadman, R.; Gornbein, J.; Lassman, C.; Holt, C. D.; Chen, P.; Farmer, D. G.; Yersiz, H.; Danino, N.; Collisson, E.; Baquarizo, A.; Han, S. S.; Saab, S.; Goldstein, L. I.; Donovan, J. A.; Esrason, K.; Busuttil, R. W. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients Ann. Surg. 2001, 234, 384-393
2. Simmonds, P. Genetic diversity and evolution of hepatitis C virus-15 years on J. Gen. Virol. 2004, 85, 3173-3188
3. Strader, D. B.; Wright, T.; Thomas, D. L.; Seeff, L. B.; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C Hepatology 2004, 39, 1147-1171
4. Manns, M. P.; Foster, G. R.; Rockstroh, J. K.; Zeuzem, S.; Zoulim, F.; Houghton, M. The way forward in HCV treatment-finding the right path Nat. Rev. Drug Discovery 2007, 6, 991-1000
5. Hézode, C.; Forestier, N.; Dusheiko, G.; Ferenci, P.; Pol, S.; Goeser, T.; Bronowicki, J. P.; Bourlière, M.; Gharakhanian, S.; Bengtsson, L.; McNair, L.; George, S.; Kieffer, T.; Kwong, A.; Kauffman, R. S.; Alam, J.; Pawlotsky, J.-M.; Zeuzem, S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N. Engl. J. Med. 2009, 360, 1839-1850
6. Kwo, P. Y.; Lawitz, E. J.; McCone, J.; Schiff, E. R.; Vierling, J. M.; Pound, D.; Davis, M. N.; Galati, J. S.; Gordon, S. C.; Ravendhran, N.; Rossaro, L.; Anderson, F. H.; Jacobson, I. M.; Rubin, R.; Koury, K.; Pedicone, L. D.; Brass, C. A.; Chaudhri, E.; Albrecht, J. K. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 2010, 376 (9742) 705-716
7. Lindenbach, B. D.; Rice, C. M. Unravelling hepatitis C virus replication from genome to function Nature 2005, 436, 933-938
8. Behrens, S.-E.; Tomei, L.; De Francesco, R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus EMBO J. 1996, 15, 12-22
9. Lohmann, V.; Korner, F.; Herian, U.; Bartenschlager, R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity J. Virol. 1997, 71, 8416-8428
10. Lesburg, C. A.; Cable, M. B.; Ferrari, E.; Hong, Z.; Mannarino, A. F.; Weber, P. C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site Nat. Struct. Biol. 1999, 6, 937-943
11. Legrand-Abravanel, F.; Nicot, F.; Izopet, J. New NS5B polymerase inhibitors for hepatitis C Expert Opin. Invest. Drugs 2010, 19 (8) 963-975
12. Sarrazin, C.; Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 2010, 138, 447-462
13. McCown, M. F.; Rajyaguru, S.; Le Pogam, S.; Ali, S.; Jiang, W.-R.; Kang, H.; Symons, J.; Cammack, N.; Najera, I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to non nucleoside polymerase or protease inhibitors Antimicrob. Agents Chemother. 2008, 52, 1604-1612
14. Kim, J.; Chong, Y. Understanding the RNA-specificity of HCV RdRp: implications for anti-HCV drug discovery Bull. Korean Chem. Soc. 2006, 27, 59-64
15. Tan, S.-L. Hepatitis C Viruses: Genomes and Molecular Biology; Horizon Bioscience: Norwich, U.K., 2006.
16. Bressanelli, S.; Tomei, L.; Rey, F. A.; De Francesco, R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides J. Virol. 2002, 76, 3482-3492
17. Klumpp, K.; Kalayanov, G.; Ma, H.; Le Pogam, S.; Leveque, V.; Jiang, W.-R.; Inocencio, N.; De Witte, A.; Rajyaguru, S.; Tai, E.; Chanda, S.; Irwin, M. R.; Sund, C.; Winqist, A.; Maltseva, T.; Eriksson, S.; Usova, E.; Smith, M.; Alker, A.; Najera, I.; Cammack, N.; Martin, J. A.; Johansson, N. G.; Smith, D. B. 2′-Deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups J. Biol. Chem. 2008, 283, 2167-2175
18. Chiacchio, U.; Borrello, L.; Crispino, L.; Rescifina, A.; Merino, P.; Macchi, B.; Balestrieri, E.; Mastino, A.; Piperno, A.; Romeo, G. Stereoselective synthesis and biological evaluations of novel 3′-deoxy-4′- azaribonucleosides as inhibitors of hepatitis C virus RNA replication J. Med. Chem. 2009, 52, 4054-4057
19. Gunic, E.; Chow, S.; Rong, F.; Ramasamy, K.; Raney, A.; Li, D. Y.; Huang, J.; Hamatake, R. K.; Hong, Z.; Girardet, J.-L. 6-Hydrazinopurine 2′-methyl ribonucleosides and their 5′-monophosphate prodrugs as potent hepatitis C virus inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 2456-2458 (Pubitemid 46507790)
20. Koch, U.; Narjes, F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase Curr. Top. Med. Chem. 2007, 7, 1302-1329 (Pubitemid 47321576)
21. Liao, X.; Butora, G.; Olsen, D. B.; Carroll, S. S.; McMasters, D. R.; Leone, J. F.; Stahlhut, M.; Doss, G. A.; Yang, L.; MacCoss, M. Synthesis of 2′-β- C -methyl-neplanocin derivatives as anti-HCV agents Tetrahedron Lett. 2008, 49, 4149-4152
22. Kim, H.-J.; Sharon, A.; Bal, C.; Wang, J.; Allu, M.; Huang, Z.; Murray, M. G.; Bassit, L.; Schinazi, R. F.; Korba, B.; Chu, C. K. Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro J. Med. Chem. 2009, 52, 206-213
23. Gane, E. J.; Rodriguez-Torres, M.; Nelson, D. R.; Jacobson, I. M.; McHutchison, J. G.; Jeffers, L.; Beard, A.; Walker, S.; Shulman, N.; Symonds, W.; Albanis, E.; Berrey, M. M. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg bid with peg-IFN and ribavirin for 28 days Hepatology 2008, 48, 1024A
24. Lalezari, J.; Gane, E.; Rodriguez-Torres, M.; De Jesus, E.; Nelson, D.; Everson, G.; Jacobson, I.; Reddy, R.; Hill, G. Z.; Beard, A.; Symonds, W. T.; Berrey, M. M.; McHutchison, J. G. Potent antiviral activity of the HCV nucleotiside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg BID for 28 days J. Hepatol. 2008, 48, S29
25. Pockros, P. J.; Nelson, D.; Godofsky, E.; Rodriguez-Torres, M.; Everson, G. T.; Fried, M. W.; Ghalib, R.; Harrison, S.; Nyberg, L.; Shiffman, M. L.; Najera, I.; Chan, A.; Hill, G. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin Hepatology 2008, 48, 385-397
26. Roberts, S. K.; Cooksley, G.; Dore, G. J.; Robson, R.; Shaw, D.; Berns, H.; Hill, G.; Klumpp, K.; Najera, I.; Washington, C. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C Hepatology 2008, 48, 398-406
27. Zhou, X. J.; Afdhal, N.; Godofsky, E.; Dienstag, J.; Rustgi, V.; Schick, L.; McInery, D.; Fielman, B. A.; Brown, N. A. Pharmacokinetics and pharmacodynamics of valopicitabine (NM283), a new nucleoside HCV polymerase inhibitor: results from a phase I/II dose-escalation trial in patients with HCV-1 infection J. Hepatol. 2005, 42, 229A
28. Carroll, S. S.; Olsen, D. B. Nucleoside analog inhibitors of hepatitis C virus replication Infect. Disord.: Drug Targets 2006, 6, 17-29
29. Smith, D. B.; Martin, J. A.; Klumpp, K.; Baker, S. J.; Blomgren, P. A.; Devos, R.; Granycome, C.; Hang, J.; Hobbs, C. J.; Jiang, W.-R.; Laxton, C.; Le Pogam, S.; Leveque, V.; Ma, H.; Maile, G.; Merrett, J. H.; Pichota, A.; Sarma, K.; Smith, M.; Swallow, S.; Symons, J.; Vesey, D.; Najera, I.; Cammack, N. Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479 Bioorg. Med. Chem. Lett. 2007, 17, 2570-2576
30. Pierra, C.; Amador, A.; Benzaria, S.; Cretton-Scott, E.; D'Amours, M.; Mao, J.; Mathieu, S.; Moussa, A.; Bridges, E. G.; Standring, D. N.; Sommadossi, J.-P.; Storer, R.; Gosselin, G. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′- C -methylcytidine J. Med. Chem. 2006, 49, 6614-6620
31. Clark, J. L.; Hollecker, L.; Mason, J. C.; Stuyver, L. J.; Tharnish, P. M.; Lostia, S.; McBrayer, T. R.; Schinazi, R. F.; Watanabe, K. A.; Otto, M. J.; Furman, P. A.; Stec, W. J.; Patterson, S. E.; Pankiewicz, K. W. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′- C -methylcytidine, a potent inhibitor of hepatitis C virus replication J. Med. Chem. 2005, 48, 5504-5508
32. Klumpp, K.; Leveque, V.; Le Pogam, S.; Ma, H.; Jiang, W.-R.; Kang, H.; Granycome, C.; Singer, M.; Laxton, C.; Hang, J. Q.; Sarma, K.; Smith, D. B.; Heindl, D.; Hobbs, C. J.; Merrett, J. H.; Symons, J.; Cammack, N.; Martin, J. A.; Devos, R.; Najera, I. The novel nucleoside analog R1479 (4′- azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture J. Biol. Chem. 2006, 281, 3793-3799
33. Smith, D. B.; Kalayanov, G.; Sund, C.; Winqvist, A.; Pinho, P.; Maltseva, T.; Morisson, V.; Leveque, V.; Rajyaguru, S.; Le Pogam, S.; Najera, I.; Benkestock, K.; Zhou, X.-X.; Maag, H.; Cammack, N.; Martin, J. A.; Swallow, S.; Johansson, N. G.; Klumpp, K.; Smith, M. The design, synthesis, and antiviral activity of 4′-azidocytidine analogues against hepatitis C virus replication: the discovery of 4′-azidoarabinocytidine J. Med. Chem. 2009, 52, 219-223
34. Pockros, P. J. New drugs for hepatitis C virus Expert Rev. Gastroenterol. Hepatol. 2007, 1, 145-154
35. Flisiak, R.; Parfieniuk, A. Investigational drugs for hepatitis C Expert Opin. Invest. Drugs 2010, 19 (1) 63-75
36. Pockros, P.; Nelson, D.; Godofsky, E.; Rodriguez-Torres, M.; Everson, G. T.; Fried, M. W.; Ghalib, R.; Harrison, S.; Nyberg, L.; Shiffman, M. L.; Chan, A.; Hill, G. High relapse rate seen at week 72 for patients treated with R1626 combination therapy Hepatology 2008, 48, 1349-1350
37. Lin, T.-I.; Lenz, O.; Fanning, G.; Verbinnen, T.; Delouvroy, F.; Scholliers, A.; Vermeiren, K.; Rosenquist, Å.; Edlund, M.; Samuelsson, B.; Vrang, L.; de Kock, H.; Wigerinck, P.; Raboisson, P.; Simmen, K. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor Antimicrob. Agents Chemother. 2009, 53, 1377-1385
38. Raboisson, P.; de Kock, H.; Rosenquist, Å.; Nilsson, M.; Salvador-Oden, L.; Lin, T.-I.; Roue, N.; Ivanov, V.; Wähling, H.; Wickström, K.; Hamelink, E.; Edlund, M.; Vrang, L.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Boutton, C.; Lenz, O.; Delouvroy, F.; Pille, G.; Surleraux, D.; Wigerinck, P.; Samuelsson, B.; Simmen, K. Structure-activity relationship study on a novel series of cyclopentane- containing macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of TMC435350 Bioorg. Med. Chem. Lett. 2008, 18, 4853-4858
39. Vandyck, K.; Cummings, M. D.; Nyanguile, O.; Boutton, C. W.; Vendeville, S.; McGowan, D.; Devogelaere, B.; Amssoms, K.; Last, S.; Rombauts, K.; Tahri, A.; Lory, P.; Hu, L.; Beauchamp, D. A.; Simmen, K.; Raboisson, P. Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase J. Med. Chem. 2009, 52, 4099-4102
40. Nyanguile, O.; Pauwels, F.; Van den Broeck, W.; Boutton, C. W.; Quirynen, L.; Ivens, T.; van der Helm, L.; Vandercruyssen, G.; Mostmans, W.; Delouvroy, F.; Dehertogh, P.; Cummings, M. D.; Bonfanti, J.-F.; Simmen, K. A.; Raboisson, P. 1,5-Benzodiazepines, a novel class of hepatitis C virus polymerase non-nucleoside inhibitors Antimicrob. Agents Chemother. 2008, 52, 4420-4431
41. Czernecki, S.; Mulard, L.; Valéry, J.-M.; Commerçon, A. Synthesis of 2′-deoxy-2′-spirocyclopropyl cytidine as potential inhibitor of ribonucleotide diphosphate reductase Can. J. Chem. 1993, 71, 413-416
42. Samano, V.; Robins, M. J. Nucleic acid and related compounds. 75. Synthesis and radical-induced ring-opening reactions of 2′-deoxyadenosine- 2′-spirocyclopropane and its uridine analogs. Mechanistic probes for ribonucleotide reductases J. Am. Chem. Soc. 1992, 114, 4007-4008
43. Petter, R. C.; Powers, D. G. Synthesis of l -2-spirocyclopropyl-2- deoxyarabinose Tetrahedron Lett. 1989, 30, 659-662
44. Ichikawa, S.; Minakawa, N.; Shuto, S.; Tanaka, M.; Sasaki, T.; Matsuda, A. Synthesis of 3′-beta-carbamoylmethylcytidine (CAMC) and its derivatives as potential antitumor agents Org. Biomol. Chem. 2006, 4, 1284-1296
45. Kodama, T.; Shuto, S.; Nomura, M.; Matsuda, A. An efficient method for the preparation of 1′alpha-branched-chain sugar pyrimidine ribonucleosides from uridine: the first conversion of a natural nucleoside into 1′-substituted ribonucleosides Chem.-Eur. J. 2001, 7, 2332-2340
46. Kaburagi, Y.; Kishi, Y. Operationally simple and efficient workup procedure for TBAF-mediated desilylation: application to halichondrin synthesis Org. Lett. 2007, 9, 723-726
47. Letters 1989, 30, 659 - 662.
48. Li, F.; Maag, H.; Alfredson, T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting J. Pharm. Sci. 2008, 97, 1109-1134
49. Balimane, P. V.; Sinko, P. J. Involvement of multiple transporters in the oral absorption of nucleoside analogues Adv. Drug Delivery Rev. 1999, 39, 183-209
50. Brandl, M.; Wu, X.; Holper, M.; Hong, L.; Jia, Z.; Birudaraj, R.; Reddy, M.; Alfredson, T.; Tran, T.; Larrabee, S.; Hadig, X.; Sarma, K.; Washington, C.; Hill, G.; Smith, D. B. Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability Drug Dev. Ind. Pharm. 2008, 34, 683-691
51. Wang, P.; Chun, B.-K.; Rachakonda, S.; Du, J.; Khan, N.; Shi, J.; Stec, W.; Cleary, D.; Ross, B. S.; Sofia, M. J. An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase J. Org. Chem. 2009, 74, 6819-6824
52. Lohmann, V.; Hoffmann, S.; Herian, U.; Penin, F.; Bartenschlager, R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture J. Virol. 2003, 77, 3007-3019
53. Halgren, T. A. MMFF VI. MMFF94s option for energy minimization studies J. Comput. Chem. 1999, 20, 720-729
54. Wojciechowski, M.; Lesyng, B. Generalized Born model: analysis, refinement, and applications to proteins J. Phys. Chem. B 2004, 108, 18368-18376
55. Rush, T. S. r.; Grant, J. A.; Mosyak, L.; Nicholls, A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction J. Med. Chem. 2005, 48, 1489-1495
56. Grant, J. A.; Gallardo, M. A.; Pickup, B. T. A fast method of molecular shape comparison: a simple application of a Gaussian description of molecular shape J. Comput. Chem. 1996, 17, 1653-1666
57. Nicholls, A.; MacCuish, N. E.; MacCuish, J. D. Variable selection and model validation of 2D and 3D molecular descriptors J. Comput.-Aided Mol. Des. 2004, 18, 451-474
58. Connolly, M. L. Analytical molecular surface calculation J. Appl. Crystallogr. 1983, 16, 548-558
59. Eldrup, A. B.; Allerson, C. R.; Bennett, C. F.; Bera, S.; Bhat, B.; Bhat, N.; Bosserman, M. R.; Brooks, J.; Burlein, C.; Carroll, S. S.; Cook, P. D.; Getty, K. L.; MacCoss, M.; McMasters, D. R.; Olsen, D. B.; Prakash, T. P.; Prhavc, M.; Song, Q.; Tomassini, J. E.; Xia, J. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase J. Med. Chem. 2004, 47, 2283-2295
60. Lohmann, V.; Körner, F.; Koch, J.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999, 285, 110-113